Royce & Associates LP Alkermes Plc. Transaction History
Royce & Associates LP
- $9.35 Billion
- Q3 2025
A detailed history of Royce & Associates LP transactions in Alkermes Plc. stock. As of the latest transaction made, Royce & Associates LP holds 49,769 shares of ALKS stock, worth $1.45 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
49,769
Previous 49,732
0.07%
Holding current value
$1.45 Million
Previous $1.42 Million
4.99%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding ALKS
# of Institutions
400Shares Held
176MCall Options Held
901KPut Options Held
400K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$297 Million0.03% of portfolio
-
State Street Corp Boston, MA8.54MShares$248 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY8.09MShares$235 Million1.98% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...